PMID- 34979777
OWN - NLM
STAT- MEDLINE
DCOM- 20220105
LR  - 20220105
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 61
IP  - 1
DP  - 2022 Jan 1
TI  - [Efficacy of total oral regimens containing ixazomib in patients with relapsed 
      and refractory multiple myeloma].
PG  - 95-98
LID - 10.3760/cma.j.cn112138-20210117-00045 [doi]
AB  - To investigate the efficacy and safety of total oral regimen containing ixazomib 
      in multidrug-resistant relapsed and refractory multiple myeloma(RRMM). A total of 
      38 patients were retrospectively analyzed from August 2018 to January 2020 in the 
      First Affiliated Hospital of Soochow University. The overall response rate 
      (ORR)was 36.8%. Among them, the very good partial response (VGPR) or better rate 
      was 23.7%, and the complete response (CR) rate was 5.3%. The ORR was 41.7% in 
      patients receiving ixazomib-lenalidomide-dexamethasone (IRD) regimen. Median PFS 
      was 5 months and median OS was 7.5 months. The ORR was 50% after second-line 
      therapy, 40% after third-line therapy and 12.5% after forth-line therapy or more. 
      The ORR was 29.0% in bortezomib-refractory patients, 38.0% in 
      lenalidomide-refractory patients, 21.4% in bortezmoib & lenalidomide dual 
      refractory patients. Grade 3-4 hematological adverse events (AEs) were reported 
      in 21% patients. Common hematological AEs included lymphopenia, neutropenia, 
      thrombocytopenia. Other usual AEs were fatigue and diarrhea. No grade 3-4 
      peripheral neuropathy was recorded. In the treatment of relapsed/refractory 
      multiple myeloma patients with multidrug resistance, the total oral regimens 
      containing ixazomib demonstrate reliable efficacy and safety. Early 
      administration of ixazomib at first or second relapse is suggested for more 
      favorable clinical outcome.
FAU - Wang, J
AU  - Wang J
AD  - Department of Hematology, Soochow Hopes Hematology Hospital, Suzhou 215128, 
      China.
FAU - Shang, J J
AU  - Shang JJ
AD  - Department of Hematology, the First Affiliated Hospital of Soochow University, 
      Jiangsu Institute of Hematology, Suzhou 215006, China.
FAU - Jin, S
AU  - Jin S
AD  - Department of Hematology, the First Affiliated Hospital of Soochow University, 
      Jiangsu Institute of Hematology, Suzhou 215006, China.
FAU - Yao, Y
AU  - Yao Y
AD  - Department of Hematology, Soochow Hopes Hematology Hospital, Suzhou 215128, 
      China.
FAU - Yan, Z
AU  - Yan Z
AD  - Department of Hematology, the First Affiliated Hospital of Soochow University, 
      Jiangsu Institute of Hematology, Suzhou 215006, China.
FAU - Wu, D P
AU  - Wu DP
AD  - Department of Hematology, Soochow Hopes Hematology Hospital, Suzhou 215128, China 
      Department of Hematology, the First Affiliated Hospital of Soochow University, 
      Jiangsu Institute of Hematology, Suzhou 215006, China.
FAU - Fu, C C
AU  - Fu CC
AD  - Department of Hematology, Soochow Hopes Hematology Hospital, Suzhou 215128, China 
      Department of Hematology, the First Affiliated Hospital of Soochow University, 
      Jiangsu Institute of Hematology, Suzhou 215006, China.
LA  - chi
GR  - 2020ZKPB01/Translational Research Grant of National Clinical Research Center of 
      Hematology/
GR  - SLJ2021004/the 12th Batch of Science and Technology Development Plan of Suzhou 
      Medical Equipments and New Medicines in 2021-Projects of Collaborative Innovation 
      in Medicine and Engineering/
PT  - Journal Article
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (Boron Compounds)
RN  - 71050168A2 (ixazomib)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Boron Compounds
MH  - Dexamethasone/therapeutic use
MH  - Glycine/analogs & derivatives
MH  - Humans
MH  - *Multiple Myeloma/drug therapy
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Retrospective Studies
EDAT- 2022/01/05 06:00
MHDA- 2022/01/06 06:00
CRDT- 2022/01/04 02:04
PHST- 2022/01/04 02:04 [entrez]
PHST- 2022/01/05 06:00 [pubmed]
PHST- 2022/01/06 06:00 [medline]
AID - 10.3760/cma.j.cn112138-20210117-00045 [doi]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2022 Jan 1;61(1):95-98. doi: 
      10.3760/cma.j.cn112138-20210117-00045.